SEC Form 4 · accession 0001501697-26-000064
X4 Pharmaceuticals, Inc · XFOR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kelly Gold
Director
Period of report
Jul 1, 2026
Accepted (ET)
Jul 1, 2026 · 4:20 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001501697
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $4.085 | Jul 1, 2026 | A | 110,000 | A | — | Jul 1, 2036 | Common Stock | 110,000 | 110,000 | D |
Explanation of responses
- F1The shares subject to the option shall vest in full on the one-year anniversary of the grant date, subject to the Reporting Person continuing to provide services through such date.